SIGNIA: An innovative drug discovery platform for rapid identification and validation of antimicrobial applications in available pharmaceutical resources and drugs open for repurposing.

Project description

An innovative platform for faster, safer and cost-efficient drug discovery

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• natural sciences › biological sciences › microbiology › virology
• social sciences › economics and business › economics › health economics › economic impact of epidemics
• medical and health sciences › health sciences › infectious diseases › RNA viruses › coronaviruses
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

SIGNIA THERAPEUTICS

Net EU contribution

€ 50 000,00

Address

L'atrium 43 Boulevard Du 11 Novembre 1918
69100 Villeurbanne
France

Region

Auvergne-Rhône-Alpes › Rhône-Alpes › Rhône

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Non-EU contribution

€ 21 429,00